Epiminder gives US clinicians a direct route to Minder EEG data

Epiminder has signed a five-year rolling partnership with Stratus Neuro to integrate its long-term Minder EEG data into StratusEEG, a cloud platform used by more than 7,000 US clinicians and administrators. The agreement gives Epiminder an established clinical workflow for its DETECT study and planned US commercialisation, although no financial terms or launch date were disclosed.

  • Five-year rolling partnership with Stratus Neuro
  • Minder data to be integrated into StratusEEG
  • Platform used by more than 7,000 US clinicians and administrators
  • Agreement extends the existing DETECT study contract
  • No contract value, exclusivity terms or commercial launch date disclosed
An image related to Epiminder Limited A photo of the logo for Epiminder Add us as a preferred source on Google
Image © middle. Logo © respective owner.

StratusEEG integration targets US clinical adoption

Epiminder Limited (ASX:EPI) is placing its long-term EEG data inside a US clinical workflow that already has scale. The medical device company has entered a five-year rolling strategic partnership with Stratus Neuro, under which data from its implantable Minder System will be integrated into StratusEEG, a cloud-based EEG review platform used by more than 7,000 US clinicians and administrators.

The arrangement extends an existing contract supporting Epiminder’s DETECT US reimbursement study. It is intended to help clinicians review Minder’s continuous, bilateral EEG recordings through software they already use, rather than requiring a separate review environment as Epiminder works towards commercialisation.

Partnership adds an established route to the commercial market

The strategic value is access to Stratus’ existing relationships with US epilepsy centres and its review infrastructure. Epiminder says this will support the DETECT program and the commercial launch of the next-generation Minder System, while a US Medicare payment decision has already established a national outpatient payment benchmark for the implant procedure from January 2027.

That combination gives the partnership a more practical commercial purpose than a simple technology link-up. Minder is designed to collect brain activity continuously over months or years, including during patients’ ordinary daily lives, while StratusEEG provides the platform for clinicians to review and interpret the resulting data. The companies will also pursue a joint research and development program.

Separate regulatory products remain in place

Epiminder and Stratus will retain separate products, regulatory clearances and manufacturers of record. Epiminder will continue to own Minder patient data. The agreement covers platform access, data services, termination, cybersecurity, warranties and confidentiality, but the announcement does not disclose its value, minimum purchase commitments, exclusivity provisions or a specific commercial launch date.

For the clinical program, the immediate test remains execution. Epiminder recently reported a 100-patient DETECT milestone, with recruitment continuing across US centres. The new platform relationship may make the data easier to use, but the announcement does not provide clinical outcomes, reimbursement revenue or evidence of clinician adoption.

Get ASX:EPI news the moment it breaks

Instant push notifications No waitlist Free
Download on the App Store iPhone & iPad
Get it on Google Play Android
Email alerts

Bottom Line?

The partnership improves Epiminder’s commercial route into US epilepsy care, but its value will depend on integration, DETECT progress and whether clinicians convert platform access into Minder use.

Questions in the middle?

  • How quickly will Minder data be integrated into StratusEEG and made available in routine clinical workflows?
  • Will the DETECT study and reimbursement pathway translate into confirmed commercial demand after launch?
  • What financial, exclusivity or minimum-volume terms sit behind the five-year rolling agreement?

Sources

1